



PH-Care

Portal Hypertension Diagnostic

 Informative Biomarkers for early detection of Portal Hypertension



? CLINICAL NEED

Advanced chronic liver disease is the 11th leading cause of death globally, with approximately 1.16 million deaths/year. **Portal hypertension (PH)** is one of its **main drivers-related clinical complications**

Current PH diagnostic methods are invasive, requires high technical skills, introduce bias and have risk of severe complications

SOLUTION

New non-invasive method for **identifying patients suffering from PH** and **stratifying** those that have **clinically significant PH**

COMPETITIVE ADVANTAGE


Non-invasive diagnosis of PH with **high sensitivity and specificity**. The method could be also used to stratify the patients according of the disease state. **No requires skilled professionals** and could be done in primary heathcare center.

INTELLECTUAL PROPERTY

International patent (PCT/EP2022/071655) application was submitted 2 of August 2022. Hospital Clínic de Barcelona, CIBER and FRCB-IDIBAPS share joint ownership.

DEVELOPMENT

Pre-clinical assays are ongoing in order to Validate the method in a relevant environment.



LOOKING FOR...

Partners for **license agreement** or **co-development**.

THE TEAM

IDIBAPS

Dr. Jordi Gracia Sancho
Group Leader

Dr. Joan Carles García-Pagan
Clinician

Clínic Barcelona

Dr. Martí Ortega Ribera
Researcher


Dra. Marta Magaz Martínez
Clinician

ciber

Dr. Albert Gibert Ramos
Researcher

MINISTERIO DE CIENCIA E INNOVACIÓN

Instituto de Salud Carlos III

 **CONTACT DETAILS**
Knowledge and Technology
Transfer Office

innova@recerca.clinic.cat